657—9.17 (147,155A) Outpatient AMDS.
	   9.17(1) Verification. All outpatient prescriptions prepared for dispensing utilizing an AMDS shall be verified, prior to being dispensed, by a pharmacist in the pharmacist’s physical presence unless a waiver is approved pursuant to subrule 9.17(2) or as provided in these rules for telepharmacy.
	   9.17(2) Waiver. A pharmacy may request waiver or variance from subrule 9.17(1) pursuant to the procedures and requirements of 657—Chapter 34. In addition to the requirements for the petition for waiver or variance identified in 657—Chapter 34, applications for waiver shall specify and include justification for the requested waiver, the methods to be used to ensure patient counseling is provided on new prescriptions pursuant to 657—8.20(155A), a quality assurance plan, and written policies and procedures for utilization of the AMDS.
	      a.    	  Quarterly reports. The quality assurance plan shall provide for submission of written quarterly reports to the board. All reports shall summarize identified errors by category and shall include the reasons for the errors, the corrective actions taken to resolve and prevent recurrence of the errors, and the average accuracy for the specified period.
	      b.    	  Verification. The quality assurance plan shall provide for verification processes for all AMDS-dispensed prescriptions.
	      c.    	  Identification of errors. The quality assurance plan shall require that all identified errors be logged as provided by the quality assurance and monitoring plan developed pursuant to rule 9.10(147,155A) and shall be categorized as follows:
	       (1)  	 Incorrect drug;
	       (2)  	 Incorrect quantity;
	       (3)  	 Incorrect dose;
	       (4)  	 Incorrect dosage form;
	       (5)  	 Incorrect directions for use;
	       (6)  	 Incorrect patient name;
	       (7)  	 Other incorrect label information;
	       (8)  	 Computer order entry error;
	       (9)  	 Other errors. All errors categorized as “other errors” shall include additional notation identifying each error.
	      d.    	  Accuracy. The performance improvement plan shall identify actions to be taken in the event that any drug error is identified.